165 related articles for article (PubMed ID: 15032565)
1. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service.
Anderson RJ
J Manag Care Pharm; 2004; 10(2):159-65. PubMed ID: 15032565
[TBL] [Abstract][Full Text] [Related]
2. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
[TBL] [Abstract][Full Text] [Related]
3. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care.
Hall D; Buchanan J; Helms B; Eberts M; Mark S; Manolis C; Peele P; Docimo A
Pharmacotherapy; 2011 Jul; 31(7):686-94. PubMed ID: 21923456
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
[TBL] [Abstract][Full Text] [Related]
5. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.
Casciano JP; Dotiwala ZJ; Martin BC; Kwong WJ
J Manag Care Pharm; 2013 May; 19(4):302-16. PubMed ID: 23627576
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration.
Wong YM; Quek YN; Tay JC; Chadachan V; Lee HK
J Clin Pharm Ther; 2011 Oct; 36(5):585-91. PubMed ID: 21070296
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system.
Darkow T; Vanderplas AM; Lew KH; Kim J; Hauch O
Curr Med Res Opin; 2005 Oct; 21(10):1583-94. PubMed ID: 16238898
[TBL] [Abstract][Full Text] [Related]
8. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
Agarwal S; Bennett D; Smith DJ
Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
[TBL] [Abstract][Full Text] [Related]
9. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
[TBL] [Abstract][Full Text] [Related]
10. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.
Sullivan PW; Arant TW; Ellis SL; Ulrich H
Pharmacoeconomics; 2006; 24(10):1021-33. PubMed ID: 17002484
[TBL] [Abstract][Full Text] [Related]
11. Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation.
Biskupiak J; Ghate SR; Jiao T; Brixner D
J Manag Care Pharm; 2013; 19(9):789-98. PubMed ID: 24156648
[TBL] [Abstract][Full Text] [Related]
12. International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.
Nelson WW; Desai S; Damaraju CV; Lu L; Fields LE; Wildgoose P; Schein JR
Curr Med Res Opin; 2014 Dec; 30(12):2437-42. PubMed ID: 25170587
[TBL] [Abstract][Full Text] [Related]
13. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T; Kaneko H; Mishina S; Wang F; Morita S
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
[TBL] [Abstract][Full Text] [Related]
14. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study.
Menzin J; Boulanger L; Hauch O; Friedman M; Marple CB; Wygant G; Hurley JS; Pezzella S; Kaatz S
Ann Pharmacother; 2005 Mar; 39(3):446-51. PubMed ID: 15701783
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two different models of anticoagulation management services with usual medical care.
Rudd KM; Dier JG
Pharmacotherapy; 2010 Apr; 30(4):330-8. PubMed ID: 20334453
[TBL] [Abstract][Full Text] [Related]
16. Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation.
Abdelhafiz AH; Wheeldon NM
Am J Geriatr Pharmacother; 2003 Dec; 1(2):53-60. PubMed ID: 15555467
[TBL] [Abstract][Full Text] [Related]
17. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System.
An J; Niu F; Zheng C; Rashid N; Mendes RA; Dills D; Vo L; Singh P; Bruno A; Lang DT; Le PT; Jazdzewski KP; Aranda G
J Manag Care Spec Pharm; 2017 Jun; 23(6):700-712. PubMed ID: 28530526
[TBL] [Abstract][Full Text] [Related]
18. Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation.
Nelson WW; Wang L; Baser O; Damaraju CV; Schein JR
J Med Econ; 2015 May; 18(5):333-40. PubMed ID: 25549062
[TBL] [Abstract][Full Text] [Related]
19. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
[TBL] [Abstract][Full Text] [Related]
20. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.
Ghate SR; Biskupiak J; Ye X; Kwong WJ; Brixner DI
J Manag Care Pharm; 2011 Nov; 17(9):672-84. PubMed ID: 22050392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
